Video

PARP Inhibitors in the Treatment of Ovarian Cancer

This Peer Exchange Webinar will provide insights into use of PARP inhibitors in the treatment of ovarian cancer.

Use of PARP inhibitors in the treatment of ovarian cancer is a promising option for many patients with advanced or recurrent disease. With multiple options available in this drug class, understanding supporting data for these products is sometimes not enough. Practical experience is incredibly valuable help ensure their optimal and appropriate use.

This Peer Exchange Webinar will provide insights into both of these subjects. Our panel of experts will also frame this conversation based on experiences from multiple practice types and how those perspectives affect clinical decision-making as well as application.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com